Jessica Flechtner

Jessica Flechtner

Company: Genocea

Job title: Chief Scientific Officer


Identification of Inhibigens™ May be the Key to Successful T Cell Therapies for Solid Tumors 11:00 am

Empirical antigen selection with ATLAS™ ensures that neoantigens are both presented by the tumor and immunogenic Inhibigens, also identified with ATLAS, are targets of pro-tumor responses and can be avoided in cell therapies GEN-011, a peripheral blood derived, neoantigen-targeted T cell therapy is currently being evaluated in patients with solid tumors in the TITAN-1 trial…Read more

day: Conference Day 1

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.